Diabetes mellitus type 2

Ensure the healthy future

Contact Us

Please fill in this form for additional information on treatment, procedures, price, etc.

About Treatment

Type 2 diabetes is a chronic disease. It is characterized by high levels of sugar in the blood. Type 2 diabetes is also called type 2 diabetes mellitus and adult-onset diabetes. That’s because it used to start almost always in middle- and late-adulthood. However, more and more children and teens are developing this condition. Type 2 diabetes is much more common than type 1 diabetes, and is really a different disease. But it shares with type 1 diabetes high blood sugar levels, and the complications of high blood sugar. During digestion, food is broken down into basic components. Carbohydrates are broken down into simple sugars, primarily glucose. Glucose is a critically important source of energy for the body’s cells. To provide energy to the cells, glucose needs to leave the blood and get inside the cells. Insulin traveling in the blood signals the cells to take up glucose. Insulin is a hormone produced by the pancreas. The pancreas is an organ in the abdomen. When levels of glucose in the blood rise (for example, after a meal), the pancreas produces more insulin. Type 2 diabetes occurs when your body’s cells resist the normal effect of insulin, which is to drive glucose in the blood into the inside of the cells. This condition is called insulin resistance. As a result, glucose starts to build up in the blood.

Scientists have not yet found a cure for type 2 diabetes. All efforts are currently focused on controlling the glucose level. It is recommended that those suffering from type 2 diabetes maintain a healthy diet and body weight, and exercise regularly to manage the disease. If diet and exercise aren’t enough to control blood glucose levels well, the patient may also need diabetes medications or insulin therapy. Researchers have been developing and adopting different stem cell approaches to treat diabetes since the early 1990s. Recent studies have demonstrated the promising results of using bone marrow mononuclear cells (MNC) and multipotent mesenchymal stem cells (MMSCs), including preserving the function of beta-cells, significant decreases of insulin dosage, and improved regeneration in patients with diabetic foot ulcers.

Improvements

Improvements that can be expected after stem cell therapy:

Significant improvement in the functioning of the pancreas

Restoration of the damaged blood vessels

General improvement of health condition

Normalization of sugar level

Immune system stimulation

Decreasing or eliminating the need for sugar-reducing medication

Consultation from a doctor for free

Get advice from a leading specialist and find out how stem cells will help you.

Feedback of the patient suffering from advanced type 2 diabetes mellitus

Patient: A.
Age: 54
Gender: Male
Diagnosis: Advanced decompensated type 2 diabetes mellitus. Ischemic heart disease: atherosclerotic cardiosclerosis, atherosclerosis of aorta and coronary atheroscelrosis. Status post coronary artery bypass graft (April 2008). Atrioventricular block, I stage. Arterial hypertension, I degree. Cardiac insufficiency I, functional class-II. Urinary stone disease: nephrolithiasis, urinary syndrome.
Country: Qatar

Patient A. underwent the stem cell treatment at our clinic. One month after the fetal stem cell transplantation the patient reported the following improvements:

  • blood pressure normalization;
  • blood sugar normalization;
  • significant improvement of ability to work: he works full time and doesn’t get tired;
  • for the first time in many years he can sleep well the whole night;
  • he stopped having pains in his heart when making love with his wife.

EmCell Clinic

The letter from the patient M.A. after the first course of treatment

Patient: M.A.
Age: 49
Gender: Male
Diagnosis: Advanced subcompensated diabetes mellitus, type 2. Hypertension. Grade III diabetic nephropathy. Grade I renal insufficiency. Ischemic heart disease (IHD): atherosclerotic cardiosclerosis. Grade IIA cardiac insufficiency. Chronic gastritis, duodenitis (incomplete remission). Deforming arthrosis of the left knee joint.
Country: UAE

After the first course of stem cell treatment, the patient wrote us the following:

Good morning,
I want to thank the staff of the clinic for the wonderful job they’ve done. I feel so good and my blood sugar is within the normal range (96-107) and 126-140 in 2 hours after eating. I want to thank God and the doctors for giving me the cure and good spirit.

Sincerely yours,
M.A.

EmCell Clinic

Bone marrow derived stem cell therapy for type 2 diabetes mellitus

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182211/

In this study, 6 patients with type 2 diabetes (T2D) underwent autologous bone marrow mononuclear stem cell (BM-MNSC) infusion into the celiac and superior mesenteric arteries without pretreatment with any myeloablative or immune-suppressive therapy. Five of 6 (83%) showed normalization of their fasting glucose and the glycosylated hemoglobin (HbA1C) with significant reduction of their medication requirements. The HbA1C dropped on average 2.2 points. The three patients with diabetic complications showed improvement or stabilization and most patients reported improved energy and stamina. The durations of response varied between 6 months and 2 years. No patients had any significant adverse effects. Keywords: Type 2 diabetes (T2D), stem cells, bone marrow mononuclear cells, glycosylated hemoglobin

A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report

http://www.bmrat.org/index.php/BMRAT/article/view/516

Introduction: Type 2 diabetes mellitus (T2DM) iscurrently one of the most common diseases as a result of obesity and aging. Currently, T2DMis treated by various methods, such as insulin injection and glucose regulation agents. In this report, we report the case of a T2DM patient who was successfully treated by autologous bone marrow-derived stem cell transplantation.

Methods: The patient was diagnosed with T2DM by standard methods for more than ten years. The patient agreed to be treated by the new approach – autologous bone marrow-derived stem cell transplantation. The bone marrow was collected from the patient twice at 100 mL volume each time. The stem cellenriched mononuclear cells (MNCs) in the bone marrow were isolated by gradient centrifugation. MNCs were intravenously transfused into the patient twice within the 1-month interval. The lasting glucose and 2h-after meal glucose, as well as hemoglobin A1c (Hab1c), were recorded before transplantation, and 1-, 3-, and 6-months post-transplantation.

Results: The results showed that there were no adverse effect recorded during the monitoring period, and that the T2DM symptoms significantly improved. After the first round of transplantation, the glucose level reduced considerably and continued to decrease out to 3 months. Meanwhile, after 2 months of transplantation, the Hab1C level decreased and achieved the average level at the 3rd month of treatment. After 6 months, the patient was free from insulin injection and maintained glucose and Hab1c level. To date, after 9 months of treatment; the patients has continued to be free from insulin injection and without any adverse effects.

Conclusion: The primary results have suggested that autologous bone marrow-derived stem cell transplantation may be a new direction for T2DM treatment.